Testing effectiveness (Phase 2)Not Yet RecruitingNCT07274384
What this trial is testing
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Hyperprogression
Università Vita-Salute San Raffaele 74